Clinical Trials Logo

Recurrent Lymphoma clinical trials

View clinical trials related to Recurrent Lymphoma.

Filter by:

NCT ID: NCT02780804 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT02465060 Active, not recruiting - Multiple Myeloma Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Start date: August 17, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

NCT ID: NCT02343718 Completed - Refractory Lymphoma Clinical Trials

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Start date: June 24, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.

NCT ID: NCT02323880 Active, not recruiting - Malignant Glioma Clinical Trials

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Start date: October 30, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT01790152 Recruiting - Osteosarcoma Clinical Trials

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Start date: March 5, 2014
Phase:
Study type: Observational

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.